Published in Clin Infect Dis on August 01, 2011
Endophthalmitis. Clin Microbiol Infect (2013) 1.79
An Ocular Commensal Protects against Corneal Infection by Driving an Interleukin-17 Response from Mucosal γδ T Cells. Immunity (2017) 1.39
Endogenous endophthalmitis: diagnosis, management, and prognosis. J Ophthalmic Inflamm Infect (2015) 1.11
Endogenous fungal endophthalmitis: risk factors, clinical features, and treatment outcomes in mold and yeast infections. J Ophthalmic Inflamm Infect (2013) 0.94
Endophthalmitis: A review of recent trends. Saudi J Ophthalmol (2012) 0.90
Invasive fungal infections in patients with cancer in the Intensive Care Unit. Int J Antimicrob Agents (2012) 0.86
Management bundles for candidaemia: the impact of compliance on clinical outcomes. J Antimicrob Chemother (2014) 0.79
Outcomes, impact on management, and costs of fungal eye disease consults in a tertiary care setting. Ophthalmology (2014) 0.78
Invasive candidiasis: from mycobiome to infection, therapy, and prevention. Eur J Clin Microbiol Infect Dis (2016) 0.78
Incidence and Risk Factors of Ocular Infection Caused by Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother (2016) 0.77
Incidence and clinical predictors of ocular candidiasis in patients with Candida fungemia. Interdiscip Perspect Infect Dis (2014) 0.76
Reply to "Why should we monitor (1-3)-β-D-glucan levels during invasive candidiasis? Just ask your ophthalmologist!". J Clin Microbiol (2013) 0.75
Prevalence and factors predictive of intraocular fungal infection in patients with fungemia at an academic urban tertiary care center. Clin Ophthalmol (2015) 0.75
Multimodal imaging of refractory Candida chorioretinitis progressing to endogenous endophthalmitis. J Ophthalmic Inflamm Infect (2015) 0.75
Study of the prevalence and association of ocular chlamydial conjunctivitis in women with genital infection by Chlamydia trachomatis, Mycoplasma genitalium and Candida albicans attending outpatient clinic. Int J Ophthalmol (2016) 0.75
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS (2009) 16.37
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis (2002) 6.13
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis (2012) 5.83
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis (2010) 5.53
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother (2003) 5.48
Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med (2009) 5.27
Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis (2005) 5.24
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15
An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol (2008) 5.13
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood (2008) 4.63
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis (2012) 4.62
Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest (2006) 4.45
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis (2003) 4.29
Invasive Candidiasis. N Engl J Med (2015) 4.18
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis (2004) 4.15
Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis (2013) 4.06
Amphotericin B: time for a new "gold standard". Clin Infect Dis (2003) 4.01
Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 3.70
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis (2002) 3.46
Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med (2008) 3.36
Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol (2004) 3.13
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med (2011) 3.11
The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe (2009) 3.07
Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol (2002) 3.03
Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood (2005) 2.97
Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med (2006) 2.86
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis (2003) 2.84
In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother (2002) 2.76
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis (2009) 2.53
Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol (2005) 2.52
Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A (2010) 2.38
Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis (2008) 2.35
Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation (2014) 2.26
Immune recognition of Candida albicans beta-glucan by dectin-1. J Infect Dis (2007) 2.24
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Discrepancies between fluorescein angiography and optical coherence tomography in macular edema in uveitis. Am J Ophthalmol (2012) 2.15
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Blastomycosis. Infect Dis Clin North Am (2003) 2.04
In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother (2002) 2.03
Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis (2003) 1.91
Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med (2012) 1.90
NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol (2004) 1.90
Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis (2006) 1.89
Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis (2007) 1.87
An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov (2010) 1.78
Endogenous interleukin (IL)-1 alpha and IL-1 beta are crucial for host defense against disseminated candidiasis. J Infect Dis (2006) 1.78
MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis (2014) 1.78
Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother (2007) 1.77
The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of Candida albicans. J Leukoc Biol (2011) 1.76
Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology (2002) 1.76
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One (2011) 1.73
Does the shape of lipid A determine the interaction of LPS with Toll-like receptors? Trends Immunol (2002) 1.72
Impact of macular edema on visual acuity in uveitis. Ophthalmology (2006) 1.72
Antifungal prophylaxis in the intensive care unit: who should get it? Crit Care Med (2006) 1.72
Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol (2003) 1.70
Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol (2011) 1.69
Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.68
A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis (2007) 1.68
Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.67
Vulvodynia: a state-of-the-art consensus on definitions, diagnosis and management. J Reprod Med (2006) 1.66
Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer (2005) 1.66
Identification of new pathogens in the intraocular fluid of patients with uveitis. Am J Ophthalmol (2010) 1.66
Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother (2003) 1.64
Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis (2009) 1.63
Long-term follow-up of intermediate uveitis in children. Am J Ophthalmol (2006) 1.62
Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother (2005) 1.61
Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. J Am Board Fam Med (2008) 1.61
Rhegmatogenous retinal detachment and uveitis. Ophthalmology (2003) 1.60
Diagnosis of ocular toxocariasis by establishing intraocular antibody production. Am J Ophthalmol (2007) 1.60
Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis (2010) 1.59
Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol (2004) 1.59